Loading page
Preview data: all rankings, scores, votes, refresh labels, methodology, testing and editorial-process statements in Top 49 are illustrative demo content, not live measurements or documented reviews.
Rank 06NewNew entry
#6 in Biggest Movers
of 16 ranked entries
Novo Nordisk
Danish pharmaceutical company · semaglutide (Ozempic, Wegovy)
Novo Nordisk’s GLP-1 drugs have become genuinely difficult to overstate as a business story — demand has repeatedly outstripped manufacturing capacity, briefly making the company Europe’s most valuable by market cap, while health systems worldwide scramble to work out how to pay for a drug class this broadly effective. Recorded specifics: category Science & health, rank change 27, home rank 3. Panel highlighted clinical results for weight management and cardiovascular risk reduction have been unusually strong across large trial populations, briefly became Europe’s most valuable public company by market capitalisation on the strength of demand alone and manufacturing capacity investment has scaled aggressively in direct response to sustained global demand. The reservation on record is persistent supply shortages have left many patients unable to access the drugs consistently, and pricing remains a major unresolved policy fight in the US specifically.
Science & healthBusiness & industry
Score breakdown
How Novo Nordisk earned 87.8
Each criterion is scored independently, then combined using the weights published on Biggest Movers.
- Magnitude of movementweight 30%
- 85.8
- Clarity of causeweight 25%
- 87.3
- Real-world consequenceweight 25%
- 88.7
- Durability of the new positionweight 20%
- 90.1
On the record
Recorded detail
| Category | Science & health |
|---|---|
| Rank change | 27 |
| Home rank | 3 |
| Momentum | 9.5 |
Panel verdict
Strengths and reservations
What it gets right
- Clinical results for weight management and cardiovascular risk reduction have been unusually strong across large trial populations
- Briefly became Europe’s most valuable public company by market capitalisation on the strength of demand alone
- Manufacturing capacity investment has scaled aggressively in direct response to sustained global demand
Where it gives ground
- Persistent supply shortages have left many patients unable to access the drugs consistently, and pricing remains a major unresolved policy fight in the US specifically
1 appearance
Where this entry ranks
From the same list
Ranked alongside it
Rank 01Editor’s pickDeepSeek
DeepSeek · open-weight models · 2023
An open-weight model that matches GPT-4-class reasoning on many benchmarks at a fraction of the API cost, which is why it forced every major lab to cut prices within weeks of release.
95.2/100 Top 49 score3Up 3
Rank 02Editor’s pickHumane AI Pin
Humane · wearable AI device, launched April 2024 — assets acquired by HP, 2025
A screenless, voice-and-projection wearable meant to reduce phone dependence, the AI Pin shipped to overwhelmingly negative reviews citing overheating, sluggish response times and a subscription fee on top of an already high device price; Humane sold its core assets to HP roughly a year after launch.
94.6/100 Top 49 score1Down 1
Rank 03Editor’s pickNorthvolt
Swedish EV battery maker · filed for bankruptcy, November 2024
Once positioned as Europe’s best hope for a homegrown battery-manufacturing champion and backed by billions from investors including Volkswagen and Goldman Sachs, Northvolt filed for Chapter 11 bankruptcy protection after production delays and quality problems it was never able to fully resolve.
93.5/100 Top 49 score3Up 3
Rank 0423andMe
Consumer genomics company · filed for bankruptcy, March 2025
The consumer DNA-testing pioneer filed for bankruptcy after years of falling demand once the novelty of at-home ancestry testing wore off, and the filing triggered widespread concern over what would happen to the genetic data of more than 15 million customers under new ownership.
91.8/100 Top 49 score3Up 3
Rank 05Fisker
American EV startup · filed for bankruptcy, June 2024
Fisker’s Ocean SUV shipped with a long list of unresolved software and safety issues, including reported brake failures, and after failing to secure a rescue investment from a major automaker, the company filed for bankruptcy roughly two years after its first customer deliveries.
90.4/100 Top 49 score2Down 2
Rank 07Waymo
Alphabet subsidiary · autonomous robotaxi service
Waymo has expanded paid robotaxi service across multiple US cities faster than any rival autonomous-driving programme, and cumulative rides have climbed into the millions with a safety record that, by the company’s own published data, now compares favourably to human drivers on a per-mile basis.
87.0/100 Top 49 score3Up 3
Rank 08Boeing
American aerospace manufacturer · ongoing safety and quality scrutiny
The January 2024 Alaska Airlines door-plug blowout reopened scrutiny of Boeing’s manufacturing quality control that the company had never fully put to rest after the 737 MAX crashes, and leadership changes, regulatory production caps and a fresh round of whistle-blower allegations have kept the story in the headlines through this year.
83.8/100 Top 49 score2Down 2
Rank 09Intuitive Machines
Houston, Texas · first US commercial Moon landing, February 2024
Intuitive Machines’ Odysseus lander became the first American spacecraft to reach the lunar surface since Apollo, tipping over on landing but still returning usable data, and a second mission the following year built directly on the lessons from that partial success as NASA’s commercial lunar delivery programme keeps gaining momentum.
82.2/100 Top 49 score2Down 2
Explore more of Top 49
Top 49 rankings are editorial. Scores are produced from the published criteria on each list and are refreshed on the cadence stated there. Figures shown across this section are curated demonstration data.